Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...
Zacks Investment Research on MSN
How is Boston Scientific's cardiovascular growth path shaping up?
Boston Scientific’s BSX Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace ...
Opinion
2dOpinion
AI Integration In MedTech Devices And Diagnostics: Regulation And Investment Opportunities
GE HealthCare Technologies Inc. (NYSE: GEHC) leads with 100 FDA-approved AI devices, concentrating heavily on imaging and diagnostics. Their CleaRecon DL technology sharpens cone-beam CT images using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback